首页|维立西呱联合重组人脑利钠肽对射血分数降低型心力衰竭患者的疗效

维立西呱联合重组人脑利钠肽对射血分数降低型心力衰竭患者的疗效

扫码查看
目的 探讨维立西呱联合重组人脑利钠肽对射血分数降低型心力衰竭(HFrEF)患者的治疗效果。方法 选取70例HFrEF患者作为研究对象,随机分为研究组(n=35)和对照组(n=35)。对照组给予HFrEF常规治疗,研究组在对照组基础上采用维立西呱联合重组人脑利钠肽治疗。比较2组治疗前后左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、氨基末端脑利钠肽前体(NT-proBNP)、6 min步行试验距离以及静息状态下的心率、收缩压和舒张压。比较2组患者治疗期间不良反应发生情况。结果 治疗后,2组LVEF高于治疗前,且研究组高于对照组,差异有统计学意义(P<0。05)。治疗后,2组LVESD、LVEDD、NT-proBNP以及静息状态下的心率、收缩压和舒张压低于治疗前,且研究组低于对照组,差异有统计学意义(P<0。05)。治疗后,2组6 min步行试验距离长于治疗前,且研究组长于对照组,差异有统计学意义(P<0。05)。2组不良反应发生情况比较,差异无统计学意义(P>0。05)。结论 维立西呱联合重组人脑利钠肽治疗可有效改善HFrEF患者心功能,且不良反应较少。
Efficacy of vericiguat combined with recombinant human brain natriuretic peptide in the treatment of heart failure patients with low ejection fraction
Objective To investigate the therapeutic effects of vericiguat in combination with re-combinant human brain natriuretic peptide in patients with heart failure with reduced ejection fraction(HFrEF).Methods Seventy patients with HFrEF were enrolled and randomly divided into study group(n=35)and control group(n=35).The control group received conventional treatment for HFrEF,while the study group was treated with vericiguat and recombinant human brain natriuretic peptide in addition to the conventional treatment.Left ventricular ejection fraction(LVEF),left ven-tricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),amino-ter-minal brain natriuretic peptide precursor(NT-proBNP),6-min walking distance as well as resting heart rate,systolic blood pressure and diastolic blood pressure were compared between the two groups before and after treatment.Adverse reactions during treatment were also compared between the two groups.Results After treatment,LVEF in two groups was significantly higher than before treatment,and the study group was significantly higher than that in the control group(P<0.05).After treat-ment,the LVESD,LVEDD,NT-proBNP as well as resting heart rate,systolic blood pressure and di-astolic blood pressure in the two groups were significantly lower than before treatment,and the study group was significantly lower than the control group(P<0.05).After treatment,the 6 min walking test distance of two groups was significantly longer than that before treatment,and the study group was significantly longer than the control group(P<0.05).There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion Vericiguat com-bined with recombinant human natriuretic peptide can effectively improve cardiac function in HFrEF patients with few adverse reactions.

heart failure with reduced ejection fractionvericiguatrecombinant human brain natriuretic peptidecardiac functionadverse reactions

黄玲芳、达迎晓、周松、狄宁宁

展开 >

河北省邢台市中心医院心血管内科,河北邢台,054500

射血分数降低型心力衰竭 维立西呱 重组人脑利钠肽 心功能 不良反应

2024

实用临床医药杂志
扬州大学,中国高校科技期刊研究会

实用临床医药杂志

CSTPCD
影响因子:1.543
ISSN:1672-2353
年,卷(期):2024.28(22)